SCHEMBL2358452

SCHEMBL2358452

NC(=O)C=Cc1cccc(Cl)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 4/20 0.73
▸ CYP2C9 P11712 2/20 0.73
▸ MAOB P27338 6/20 0.63
▸ MEN1 O00255 4/20 0.57
▸ KMT2A Q03164 4/20 0.57
▸ NPC1 O15118 3/20 0.57
▸ RAB9A P51151 3/20 0.57
▸ SMN1; SMN2 Q16637 3/20 0.57
▸ CYP3A4 P08684 2/20 0.57
▸ CYP2C19 P33261 2/20 0.57
▸ MAOA P21397 3/20 0.56
▸ CYP2D6 P10635 2/20 0.56
▸ CYP1A1 P04798 2/20 0.56
▸ CYP1B1 Q16678 2/20 0.56
▸ LMNA P02545 1/20 0.55
▸ GRIN1 Q05586 1/20 0.54
▸ GRIN2B Q13224 1/20 0.54
▸ MAPT P10636 1/20 0.52
▸ ALDH1A1 P00352 2/20 0.51
▸ HPGD P15428 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5046640 1.00 CYP1A2 (0.73) CYP1A2CYP2C9MAOBMEN1KMT2A
SCHEMBL4398128 0.86 NPSR1 (0.55) CYP1A2CYP2C9MAOBSMN1; SMN2CYP2D6
SCHEMBL31553466 0.85 CYP1A2 (1.00) CYP1A2CYP2C9MAOBMEN1KMT2A
SCHEMBL5598566 0.85 CYP1A2 (1.00) CYP1A2CYP2C9MAOBMEN1KMT2A
SCHEMBL22596713 0.85 CYP1A2 (0.79) CYP1A2CYP2C9MAOBMEN1KMT2A
SCHEMBL5598564 0.85 CYP1A2 (1.00) CYP1A2CYP2C9MAOBMEN1KMT2A
3-Chloro-Cinnamic Acid SCHEMBL22396853 0.83 CYP1A2 (0.76) CYP1A2CYP2C9MAOBMEN1KMT2A
3-Chloro-Cinnamic Acid SCHEMBL79592 0.83 CYP1A2 (0.76) CYP1A2CYP2C9MAOBMEN1KMT2A
SCHEMBL1556592 0.83 CYP1A2 (0.76) CYP1A2CYP2C9MAOBMEN1KMT2A
3-Chloro-Cinnamic Acid SCHEMBL79591 0.83 CYP1A2 (0.76) CYP1A2CYP2C9MAOBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116768792-B Cinnamamide-hydroxypyridone derivative, and preparation method and application thereof 浙江工业大学 2024-10-18 — — CN disclosed
CN-117396474-A Plasma kallikrein inhibitors 武田药品工业株式会社 2024-01-12 — — CN disclosed
CN-116768792-A Cinnamamide-hydroxypyridone derivative, and preparation method and application thereof 浙江工业大学 2023-09-19 — — CN disclosed
CN-109836383-B Method for preparing 3, 4-dihydroquinoline-2 (1H) -ketone compound 安徽理工大学 2022-04-19 — — CN disclosed
EP-2349982-A1 ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION Congenia S.r.l. (IT) 2011-08-03 — — EP disclosed
WO-2010049768-A1 ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION CONGENIA SRL (IT) 2010-05-06 — — WO disclosed
US-7442702-B2 Treatment of bone disorders; carboxy derivatives PFIZER INC. (US) 2008-10-28 — — US disclosed
EP-1021410-B1 PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS PFIZER (US) 2006-12-27 — — EP disclosed
EP-0946501-B1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER (US) 2006-05-31 — — EP disclosed
US-6998423-B2 Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER INC. (US) 2006-02-14 — — US disclosed
EP-1021410-A1 PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS PFIZER INC. (US) 2000-07-26 — — EP disclosed
EP-1000619-A2 Method for treating glaucoma Pfizer Products Inc. (US) 2000-05-17 — — EP disclosed
US-RE36625-E Linear and cyclic polymers or oligomers having a photoreactive ethene group ROLIC AG (CH) 2000-03-21 — — US disclosed
CN-1241176-A Prevention of loss and restoration of bone mass by certain prostaglandin agonists PFIZER (US) 2000-01-12 — — CN disclosed
EP-0946501-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1999-10-06 — — EP disclosed
WO-1999019300-A1 PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS PFIZER INC. (US) 1999-04-22 — — WO disclosed
WO-1998028264-A1 PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-07-02 — — WO disclosed
US-5539074-A LIQUID CRYSTAL POLYMERS ON SILICA FOR LIGHT SENSITIVE ELEMENTS HOFFMANN-LA ROCHE INC. (US) 1996-07-23 — — US disclosed
CN-1040366-A Butenoic acid or acrylic acid derivative EISAI CO LTD (JP) 1990-03-14 — — CN disclosed
US-4012377-A ANTIMICROBIAL, PARASITICIDES GLAXO LABORATORIES LIMITED (EN) 1977-03-15 — — US disclosed
Send feedback